Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 5;5(7):e639.
doi: 10.1002/mco2.639. eCollection 2024 Jul.

Gene editing therapy for cardiovascular diseases

Xinyu Wu  1 , Jie Yang  1 , Jiayao Zhang  1 , Yuning Song  1
Affiliations
Review

Gene editing therapy for cardiovascular diseases

Xinyu Wu et al. MedComm (2020). .

Abstract

The development of gene editing tools has been a significant area of research in the life sciences for nearly 30 years. These tools have been widely utilized in disease detection and mechanism research. In the new century, they have shown potential in addressing various scientific challenges and saving lives through gene editing therapies, particularly in combating cardiovascular disease (CVD). The rapid advancement of gene editing therapies has provided optimism for CVD patients. The progress of gene editing therapy for CVDs is a comprehensive reflection of the practical implementation of gene editing technology in both clinical and basic research settings, as well as the steady advancement of research and treatment of CVDs. This article provides an overview of the commonly utilized DNA-targeted gene editing tools developed thus far, with a specific focus on the application of these tools, particularly the clustered regularly interspaced short palindromic repeat/CRISPR-associated genes (Cas) (CRISPR/Cas) system, in CVD gene editing therapy. It also delves into the challenges and limitations of current gene editing therapies, while summarizing ongoing research and clinical trials related to CVD. The aim is to facilitate further exploration by relevant researchers by summarizing the successful applications of gene editing tools in the field of CVD.

Keywords: CRISPR/Cas; cardiovascular disease; gene therapy; lipid nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no conflict of interest exists.

Figures

FIGURE 1
FIGURE 1
The discovery and development of the CRISPR/Cas system. The CRISPR system has rapidly expanded since its initial discovery, emerging as a crucial tool for gene editing therapies. Abbreviations: ABE, Adenine Base Editor; CBE, Cytidine Base Editor; CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR‐associated.
FIGURE 2
FIGURE 2
The application of the CRISPR/Cas system for gene editing therapy in CVD. A variety of gene editing systems centered on the CRISPR/Cas system have demonstrated effective gene editing outcomes in various animal models targeting key genes of CVDs with different delivery methods, and furthermore have achieved initial successes in gene editing therapies for CVDs in human clinics. Abbreviations: DMD, dystrophin; LDL‐C, low‐density lipoprotein cholesterol; TG, triglyceride; TTR, transthyretin.
See this image and copyright information in PMC

References

    1. Mendel G. Experiments in plant hybridization. Meetings of the Natural Science Society . February/March 1965.
    1. Roll‐Hansen N. The crucial experiment of Wilhelm Johannsen. Biol Philos. 1989;4(3):303‐329.
    1. Szybalska EH, Szybalski W. Genetics of human cell lines, IV. DNA‐mediated heritable transformation of a biochemical trait. P Natl Acad Sci USA. 1962;48(12):2026‐2034. - PMC - PubMed
    1. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte‐directed gene therapy for ADA$^‐$ SCID: initial trial results after 4 years. Science. 1995;270(5235):475‐480. - PubMed
    1. Song X, Liu C, Wang N, et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Adv Drug Deliv Rev. 2021;168:158‐180. - PubMed

LinkOut - more resources